Keeley Teton Advisors LLC Has $1.84 Million Holdings in Bath & Body Works, Inc. (NYSE:BBWI)

Keeley Teton Advisors LLC trimmed its stake in Bath & Body Works, Inc. (NYSE:BBWI) by 3.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,346 shares of the company’s stock after selling 1,659 shares during the period. Keeley Teton Advisors LLC’s holdings in Bath & Body Works were worth $1,836,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. Golden State Wealth Management LLC bought a new position in Bath & Body Works during the fourth quarter valued at about $26,000. SRS Capital Advisors Inc. raised its stake in shares of Bath & Body Works by 99.7% in the fourth quarter. SRS Capital Advisors Inc. now owns 659 shares of the company’s stock valued at $26,000 after purchasing an additional 329 shares in the last quarter. UMB Bank n.a. lifted its position in Bath & Body Works by 58.8% in the fourth quarter. UMB Bank n.a. now owns 905 shares of the company’s stock worth $35,000 after purchasing an additional 335 shares during the period. Lindbrook Capital LLC boosted its stake in Bath & Body Works by 81.9% during the fourth quarter. Lindbrook Capital LLC now owns 957 shares of the company’s stock worth $37,000 after buying an additional 431 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new stake in Bath & Body Works in the 3rd quarter valued at $39,000. Institutional investors and hedge funds own 95.14% of the company’s stock.

Bath & Body Works Stock Performance

BBWI opened at $27.66 on Wednesday. The company has a fifty day moving average price of $32.60 and a two-hundred day moving average price of $33.93. The firm has a market capitalization of $5.92 billion, a PE ratio of 6.75, a P/E/G ratio of 0.92 and a beta of 1.69. Bath & Body Works, Inc. has a 52 week low of $24.96 and a 52 week high of $52.99.

Bath & Body Works (NYSE:BBWI) last released its quarterly earnings data on Thursday, February 27th. The company reported $2.09 EPS for the quarter, beating analysts’ consensus estimates of $2.04 by $0.05. Bath & Body Works had a negative return on equity of 44.03% and a net margin of 12.43%. The business had revenue of $2.79 billion during the quarter, compared to the consensus estimate of $2.78 billion. Equities analysts forecast that Bath & Body Works, Inc. will post 3.3 EPS for the current year.

Bath & Body Works Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, March 7th. Shareholders of record on Friday, February 21st were issued a $0.20 dividend. The ex-dividend date of this dividend was Friday, February 21st. This represents a $0.80 annualized dividend and a yield of 2.89%. Bath & Body Works’s dividend payout ratio (DPR) is presently 21.98%.

Bath & Body Works announced that its Board of Directors has approved a stock buyback program on Thursday, February 27th that allows the company to buyback $500.00 million in outstanding shares. This buyback authorization allows the company to buy up to 6.4% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s management believes its stock is undervalued.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Citigroup reduced their price objective on shares of Bath & Body Works from $48.00 to $36.00 and set a “buy” rating for the company in a report on Monday, April 7th. Piper Sandler raised Bath & Body Works from a “neutral” rating to an “overweight” rating and decreased their price objective for the company from $38.00 to $35.00 in a report on Wednesday, April 9th. Wells Fargo & Company raised Bath & Body Works from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $42.00 to $48.00 in a report on Friday, January 10th. Argus reiterated a “hold” rating on shares of Bath & Body Works in a research report on Friday, January 10th. Finally, Raymond James reiterated an “outperform” rating and set a $46.00 target price (up previously from $42.00) on shares of Bath & Body Works in a research report on Tuesday, February 25th. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.69.

Bath & Body Works Profile

Bath & Body Works, Inc is a specialty retailers and home to America’s Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.